|
| 37490381 | Evaluating the Predictive Value of Glioma Growth Models for Low-Grade Glioma After Tumor Resection. | IEEE Trans Med Imaging | 2024 |
| 35046557 | Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. | Prostate Cancer Prostatic Dis | 2023 |
| 38024241 | Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort. | Neurooncol Adv | 2023 |
| 37738997 | Primary brain tumours in adults. | Lancet | 2023 |
| 35788352 | Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning. | Neuro Oncol | 2023 |
| 37279174 | Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. | Neuro Oncol | 2023 |
| 37441086 | Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated <i>TERT</i> promoter mutation. | Neurooncol Adv | 2023 |
| 36920679 | Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol. | J Neurooncol | 2023 |
| 36571817 | Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033. | Neuro Oncol | 2023 |
| 36898379 | Transcriptome analysis reveals tumor microenvironment changes in glioblastoma. | Cancer Cell | 2023 |
| 36702828 | Author Correction: Federated learning enables big data for rare cancer boundary detection. | Nat Commun | 2023 |
| 36632791 | EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. | Neuro Oncol | 2023 |
| 35972438 | IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas. | Neuro Oncol | 2023 |
| 34608482 | The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis. | Neuro Oncol | 2022 |
| 35731991 | Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. | J Clin Oncol | 2022 |
| 35523140 | Human branching cholangiocyte organoids recapitulate functional bile duct formation. | Cell Stem Cell | 2022 |
| 36590163 | Alternative normalization and analysis pipeline to address systematic bias in NanoString GeoMx Digital Spatial Profiling data. | iScience | 2022 |
| 36446943 | Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation. | Nature | 2022 |
| 36470898 | Federated learning enables big data for rare cancer boundary detection. | Nat Commun | 2022 |
| 36207287 | 3D-Engineered Scaffolds to Study Microtubes and Localization of Epidermal Growth Factor Receptor in Patient-Derived Glioma Cells. | Small | 2022 |
| 36131014 | Failure of human rhombic lip differentiation underlies medulloblastoma formation. | Nature | 2022 |
| 35990704 | The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review. | Neurooncol Adv | 2022 |
| 36152406 | Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review. | Eur J Cancer | 2022 |
| 35099533 | MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. | Neuro Oncol | 2022 |
| 35148843 | Genetic and epigenetic determinants of reactivation of Mecp2 and the inactive X chromosome in neural stem cells. | Stem Cell Reports | 2022 |
| 35275197 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. | Clin Cancer Res | 2022 |
| 35294545 | Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. | Clin Cancer Res | 2022 |
| 35322237 | Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. | Nat Rev Clin Oncol | 2022 |
| 32609812 | Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. | Neuro Oncol | 2021 |
| 33741928 | The transcriptional landscape of Shh medulloblastoma. | Nat Commun | 2021 |
| 33740099 | Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. | Acta Neuropathol | 2021 |
| 33704479 | You spin me right 'round. | Neuro Oncol | 2021 |
| 33914057 | Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. | Neuro Oncol | 2021 |
| 34891161 | Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA-minus RNA sequencing data. | Gigascience | 2021 |
| 35047820 | Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas. | Neurooncol Adv | 2021 |
| 34409497 | Subgroup and subtype-specific outcomes in adult medulloblastoma. | Acta Neuropathol | 2021 |
| 34749299 | Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. | EBioMedicine | 2021 |
| 34595478 | Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures. | Neurooncol Adv | 2021 |
| 34827570 | Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing. | Biomolecules | 2021 |
| 34159239 | The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma. | Data Brief | 2021 |
| 33952518 | SMARCAD1-mediated active replication fork stability maintains genome integrity. | Sci Adv | 2021 |
| 34170285 | Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. | Blood Adv | 2021 |
| 34000245 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. | Lancet Oncol | 2021 |
| 33293629 | EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. | Nat Rev Clin Oncol | 2021 |
| 32512509 | Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors. | EBioMedicine | 2020 |
| 31637414 | Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. | Neuro Oncol | 2020 |
| 31747009 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. | Neuro Oncol | 2020 |
| 32076030 | Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. | Sci Rep | 2020 |
| 31743054 | Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. | J Clin Oncol | 2020 |
| 33375286 | Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. | Cancers (Basel) | 2020 |